Our mission is to make biology easier to engineer. Ginkgo is constructing, editing, and redesigning the living world in order to answer the globe’s growing challenges in health, energy, food, materials, and more. Our bioengineers make use of an in-house automated foundry for designing and building new organisms. 

Ginkgo Bioworks is a publicly traded (NYSE: $DNA), high-growth biotechnology company based in Boston’s Seaport District, that is redesigning the living world to solve some of the globe’s growing challenges poised to disrupt multiple industries by leveraging our innovative data, automation, and scale capabilities in biological engineering. 

Ginkgo believes that if we are to grow a thriving, sustainable bioeconomy, we must also grow a new market in biosecurity. Our biosecurity and public health initiative, Concentric by Ginkgo, launched a nationwide emergency response to the COVID-19 pandemic, providing end-to-end pathogen monitoring services to schools, communities, and travelers. As we continue to scale Concentric, our work is also evolving into new and exciting directions, from global ...